The need for a reliable bone biomarker to better assess chronic kidney disease mineral and bone disorder

Tolouian, Ramin; Gupta, Ajay

doi:10.15171/jpd.2018.14

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic kidney disease, mineral bone disorder (CKD-MBD) is a metabolic bone disease present in almost all uremic patients. With uremia, bone is relatively resistant to parathyroid hormone (PTH) action, such that the average level of PTH is required to maintain bone turnover [2]. Relative hypoparathyroidism is associated with low-turnover or a dynamic bone disease [3] ; severe secondary hyperparathyroidism leads to high turnover bone disease [4] .…”

Section: Introductionmentioning

confidence: 99%

Hormonal and Mineral Imbalance Effect on Bone Resorption in Predialysis Iraqi Patients with Chronic Kidney Disease

2020

IJFMT

View full text Add to dashboard Cite

Introduction: Chronic kidney disease mineral bone disorder is a metabolic bone disease present in almost all uremic patients. The aim of this research to indicate the stage of chronic kidney disease (CKD) that affect the bone metabolism that leading to the mineral and hormonal imbalance by studying the relationship among osteocalcin , glomerular filtration rate (GFR), parathyroid hormone, calcium and phosphorus levels in the blood. Method:The study included 52 patients with predialysis chronic kidney disease stage 3-5 and 40 apparently healthy relatives accompanying the patients. Glomerular filtration rate (GFR) was calculated for each patient. Renal function tests, including serum levels of urea, creatinine, a biochemical marker of bone metabolism: osteocalcin (OSN), calcium, phosphorus, and parathyroid hormone (PTH), were measured for each participant.Results: Serum urea and creatinine levels were significantly higher in CKD patients Than that of apparently healthy control. There is significantly higher serum parathyroid hormone, serum phosphorus, serum osteocalcin (P<0.01, P<0.01, P<0.01 respectively) in CKD patients than that of the healthy control group. While low serum calcium level in CKD patients as compared to the corresponding group (P<0.01). Conclusion:Hyperphosphatemia and hypocalcemia in the end stage of predialysis CKD patients lead to increase parathyroid hormone secretion, which causes high bone turnover characterized by significantly high serum osteocalcin in these patients. Parathyroid hormone and osteocalcin were used as a biomarker for the development of bone and mineral disorders in predialysis CKD patients.

show abstract

Section: Introductionmentioning

confidence: 99%